[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650489":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":19,"locations":20,"responsibleParty":41,"collaborators":19,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":19,"eligibilityCriteria":50,"healthyVolunteers":47,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":19,"studyType":57,"phases":58,"briefSummary":61,"conditions":62,"keywords":19,"overallStatus":23,"whyStopped":19,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"University of Sao Paulo","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ayahuasca","EXPERIMENTAL","single oral dose of ayahuasca (1 ml\u002Fkg)",[13],"Drug: Ayahuasca",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Oral dose of ayahuasca (1 ml\u002Fkg)",[9],null,[21],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Ribeirão Preto Medical School","RECRUITING","Ribeirão Preto","São Paulo","14048900","Brazil","BR",{"type":30,"coordinates":31},"Point",[32,33],-47.81028,-21.1775,{"lat":33,"lon":32},[36],{"name":37,"role":38,"phone":39,"phoneExt":19,"email":40},"Rafael dos Santos, PhD","CONTACT","+551636022703","banisteria@gmail.com",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Rafael Guimarães dos Santos","PhD, Professor","100650489","phase-1-effects-of-a-sigle-dose-of-ayahuasca-in-patients-with-psychogenic-non-epileptic-seizures-an-open-label-clinical-trial-100650489",false,"NCT07747324","Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial","Inclusion Criteria:\n\n* Patients aged 18 to 60 with documented PNES (confirmed via VEEG), without a diagnosis of comorbid epilepsy, and currently receiving follow-up care at outpatient clinics. To enroll in the study, patients must undergo a gradual reduction and discontinuation of any psychotropic medications (antidepressants, antipsychotics, benzodiazepines, or mood stabilizers\u002Fanticonvulsants) they are currently taking, in order to avoid drug interactions with-or influence on-the effects of ayahuasca.\n\nExclusion Criteria:\n\n* Patients who have not experienced psychogenic seizures in the last 3 months; patients diagnosed with epilepsy; patients who refuse to reduce or discontinue their current psychotropic medications; patients with a history of prior ayahuasca use; patients with a history of substance use disorder; patients who refuse to sign the Informed Consent Form; patients with schizophrenia or other psychotic disorders and\u002For impaired reality testing; and pregnant or breastfeeding women.","ALL","18 Years","60 Years",{"count":55,"type":56},15,"ESTIMATED","INTERVENTIONAL",[59,60],"PHASE1","PHASE2","Open label intervention with a single dose of ayahuasca in patients with psychogenic non-epileptic seizures (PNES)",[63],"Non Epileptic Seizures","2026-07-30",{"date":66,"type":67},"2026-08-05","ACTUAL",{"date":69,"type":67},"2026-07-01",{"date":71,"type":56},"2027-08-30",{"name":5,"class":6},1]